Cell treatment on track for Phase II stroke trial

04/27/2012 | ProactiveInvestors.co.uk (U.K.)

The stem cell therapy ReN001 is being used in early clinical trials to treat 12 patients disabled by stroke, and an application is on track for a midstage study in 2013. The therapy is based on stem cell developer ReNeuron's lead neural stem cell line. ReNeuron is also developing treatments for peripheral arterial disease and retina diseases.

View Full Article in:

ProactiveInvestors.co.uk (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID